Etzer Darout
Stock Analyst at BMO Capital
(2.12)
# 2,794
Out of 4,868 analysts
111
Total ratings
36.9%
Success rate
-3.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals | Maintains: Outperform | $26 → $15 | $3.90 | +284.62% | 5 | May 13, 2025 | |
| VERV Verve Therapeutics | Maintains: Buy | $18 → $24 | $11.38 | +110.90% | 2 | Apr 15, 2025 | |
| IVA Inventiva | Maintains: Buy | $12 → $9 | $3.44 | +162.01% | 3 | Apr 4, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $82 → $20 | $7.48 | +167.38% | 4 | Mar 12, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Outperform | $62 → $72 | $55.21 | +30.41% | 2 | Mar 11, 2025 | |
| BNTX BioNTech SE | Maintains: Outperform | $130 → $143 | $104.97 | +36.23% | 4 | Mar 11, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $22 → $3 | $1.61 | +86.34% | 3 | Feb 11, 2025 | |
| IGMS IGM Biosciences | Downgrades: Market Perform | $21 → $2 | $1.19 | +68.07% | 2 | Jan 10, 2025 | |
| EXEL Exelixis | Downgrades: Market Perform | $36 → $40 | $41.36 | -3.28% | 3 | Dec 20, 2024 | |
| TRML Tourmaline Bio | Initiates: Outperform | $50 | $18.18 | +175.03% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $11.39 | +207.29% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $55 | $46.35 | +18.66% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $5.41 | +1,064.51% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $27 | $1.21 | +2,131.40% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $76.06 | +76.18% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $32 → $34 | $8.31 | +309.15% | 5 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $22.03 | +117.88% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $116.41 | +3.08% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $38 | $31.15 | +21.99% | 3 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $25 | $4.80 | +420.83% | 6 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $5 | $1.54 | +224.68% | 9 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $1.49 | +1,242.28% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $91 | $53.08 | +71.44% | 5 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $1.20 | +400.00% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $3.25 → $3.59 | $2.38 | +50.84% | 10 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $70.97 | +15.54% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $4.79 | +296.66% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $308.71 | -44.93% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $54 | $55.40 | -2.53% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $50.70 | -25.05% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $1.40 | +3,614.29% | 1 | Mar 28, 2018 |
Terns Pharmaceuticals
May 13, 2025
Maintains: Outperform
Price Target: $26 → $15
Current: $3.90
Upside: +284.62%
Verve Therapeutics
Apr 15, 2025
Maintains: Buy
Price Target: $18 → $24
Current: $11.38
Upside: +110.90%
Inventiva
Apr 4, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $3.44
Upside: +162.01%
Arvinas
Mar 12, 2025
Maintains: Outperform
Price Target: $82 → $20
Current: $7.48
Upside: +167.38%
Protagonist Therapeutics
Mar 11, 2025
Reiterates: Outperform
Price Target: $62 → $72
Current: $55.21
Upside: +30.41%
BioNTech SE
Mar 11, 2025
Maintains: Outperform
Price Target: $130 → $143
Current: $104.97
Upside: +36.23%
Q32 Bio
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $1.61
Upside: +86.34%
IGM Biosciences
Jan 10, 2025
Downgrades: Market Perform
Price Target: $21 → $2
Current: $1.19
Upside: +68.07%
Exelixis
Dec 20, 2024
Downgrades: Market Perform
Price Target: $36 → $40
Current: $41.36
Upside: -3.28%
Tourmaline Bio
Dec 6, 2024
Initiates: Outperform
Price Target: $50
Current: $18.18
Upside: +175.03%
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $11.39
Upside: +207.29%
Dec 6, 2024
Initiates: Market Perform
Price Target: $55
Current: $46.35
Upside: +18.66%
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $5.41
Upside: +1,064.51%
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $1.21
Upside: +2,131.40%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $76.06
Upside: +76.18%
Nov 8, 2024
Reiterates: Outperform
Price Target: $32 → $34
Current: $8.31
Upside: +309.15%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $22.03
Upside: +117.88%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $116.41
Upside: +3.08%
Oct 11, 2024
Maintains: Outperform
Price Target: $34 → $38
Current: $31.15
Upside: +21.99%
Aug 13, 2024
Maintains: Outperform
Price Target: $26 → $25
Current: $4.80
Upside: +420.83%
Aug 7, 2024
Maintains: Market Perform
Price Target: $8 → $5
Current: $1.54
Upside: +224.68%
Aug 6, 2024
Reiterates: Outperform
Price Target: $20
Current: $1.49
Upside: +1,242.28%
Jun 4, 2024
Maintains: Outperform
Price Target: $84 → $91
Current: $53.08
Upside: +71.44%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $1.20
Upside: +400.00%
May 9, 2024
Maintains: Market Perform
Price Target: $3.25 → $3.59
Current: $2.38
Upside: +50.84%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $70.97
Upside: +15.54%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $4.79
Upside: +296.66%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $308.71
Upside: -44.93%
Feb 26, 2021
Initiates: Buy
Price Target: $54
Current: $55.40
Upside: -2.53%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $50.70
Upside: -25.05%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $1.40
Upside: +3,614.29%